SCHEMBL640865

SCHEMBL640865

NC(=NO)c1cnccn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 1/20 0.57
ADORA3 P0DMS8 1/20 0.57
TSHR P16473 1/20 0.57
MC4R P32245 1/20 0.57
ADRA1A P35348 1/20 0.57
MC3R P41968 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.56
KDM4E B2RXH2 3/20 0.48
NAPRT Q6XQN6 1/20 0.48
HCAR2 Q8TDS4 1/20 0.48
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
HSP90AA1 P07900 1/20 0.44
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
GAA P10253 1/20 0.36
MCL1 Q07820 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL640864 1.00 BAZ2B (0.57) BAZ2BADORA3TSHRMC4RADRA1A
SCHEMBL6449733 0.83 BAZ2B (0.57) BAZ2BADORA3TSHRMC4RADRA1A
SCHEMBL24170740 0.81 BAZ2B (0.55) BAZ2BADORA3TSHRMC4RADRA1A
SCHEMBL22281919 0.78 SMN1; SMN2 (0.56) BAZ2BADORA3TSHRMC4RADRA1A
SCHEMBL4468769 0.76 SMN1; SMN2 (0.54) BAZ2BADORA3TSHRMC4RADRA1A
SCHEMBL4468773 0.76 SMN1; SMN2 (0.54) BAZ2BADORA3TSHRMC4RADRA1A
SCHEMBL29775332 0.76 KDM4E (0.56) BAZ2BADORA3TSHRMC4RADRA1A
SCHEMBL14434128 0.74 KDM4E (0.53) BAZ2BADORA3TSHRMC4RADRA1A
Pyrazinamide SCHEMBL28605056 0.74 ADORA3 (0.91) BAZ2BADORA3TSHRMC4RADRA1A
SCHEMBL6748574 0.74 KDM4E (0.53) BAZ2BADORA3TSHRMC4RADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4041727-B1 ATF6 MODULATORS AND USES THEREOF ALTOS LABS INC (US) 2026-05-20 EP disclosed
EP-4363415-B1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) 2025-12-10 EP disclosed
CN-119823112-A ATF6 modulators and uses thereof 阿尔托斯实验室公司 2025-04-15 CN disclosed
CN-115135645-B ATF6 modulators and uses thereof 阿尔托斯实验室公司 2024-12-27 CN disclosed
US-20240279217-A1 Heterocyclic compounds for the treatment of tuberculosis TECNIMEDE - Sociedade Técnico-medicinal, SA (PT) 2024-08-22 US disclosed
CN-114450281-B Inhibitor compounds 辛塞拉治疗私人有限公司 2024-08-16 CN disclosed
EP-4363415-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS Tecnimede, Sociedade Técnico-Medicinal, SA (PT) 2024-05-08 EP disclosed
WO-2023141114-A2 SYNTHESIS OF BORON-CONTAINING AMIDOXIME REAGENTS AND THEIR APPLICATION TO SYNTHESIZE FUNCTIONALIZED OXADIAZOLE AND QUINAZOLINONE DERIVATIVES LONG ISLAND UNIVERSITY (US) 2023-07-27 WO disclosed
WO-2023275744-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS TECNIMEDE - Sociedade Técnico-medicinal, SA (PT) 2023-01-05 WO disclosed
WO-2023275744-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS TECNIMEDE - Sociedade Técnico-medicinal, SA (PT) 2023-01-05 WO disclosed
CN-1349485-A Glucocorticoid receptor modulators PFIZER PROD INC (US) 2002-05-15 CN disclosed
WO-2002036555-A1 SULFAMIDES AS GAMMA-SECRETASE INHIBITORS MERCK SHARP & DOHME LIMITED (GB) 2002-05-10 WO disclosed
US-6380223-B1 FOR THERAPY OF DISEASES, SUCH AS OBESITY, DIABETES, INFLAMMATION PFIZER INC. 2002-04-30 US disclosed
EP-1175383-A1 GLUCOCORTICOID RECEPTOR MODULATORS Pfizer Products Inc. (US) 2002-01-30 EP disclosed
WO-2001014333-A1 SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA UK LIMITED (GB) 2001-03-01 WO disclosed
WO-2000066522-A1 GLUCOCORTICOID RECEPTOR MODULATORS PFIZER PRODUCTS INC. (US) 2000-11-09 WO disclosed
US-3935211-A CNS DEPRESSANT AMERICAN CYANAMID COMPANY (US) 1976-01-27 US disclosed
US-3935211-A CNS DEPRESSANT AMERICAN CYANAMID COMPANY (US) 1976-01-27 US disclosed
US-3906097-A Method of producing a depressant effect using 5-cyclopropyl-1,2,4-oxadiazol-3-yl diazines AMERICAN CYANAMID CO 1975-09-16 US disclosed
US-3857843-A CYCLOPROPYL 1,2,4-OXADIAZOLYLDIAZINES AMERICAN CYANAMID CO 1974-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279217-A1 Heterocyclic compounds for the treatment of tuberculosis SDHA, NQO1, FNTB BAZ2B 1440/4885ADORA3 3314/4885TSHR 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.